The APOO Knockout HT29 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma cell line, engineered for the targeted disruption of the APOO gene. This loss-of-function model enables the study of APOO-dependent processes without the introduction of a specific clonal mutation, providing a mixed population that may reflect heterogeneous knockout efficiencies suitable for pooled functional analyses. The polyclonal format is generated via non-homologous end joining following Cas9-mediated double-strand breaks, resulting in a diverse array of indel mutations across the cell pool.
HT29 is a widely characterized human colorectal adenocarcinoma cell line originating from a primary tumor of a 44-year-old female. Exhibiting an epithelial morphology, this cell line is capable of enterocytic differentiation under appropriate culture conditions and serves as a well-established model for intestinal epithelial biology and colorectal cancer research. HT29 cells are commonly employed to investigate oncogenic signaling, drug response, and metabolic adaptations in colon cancer, making them an appropriate host for dissecting the contributions of APOO in a disease-relevant context.
APOO encodes a dual-function protein that operates both as a structural component of the mitochondrial contact site and cristae organizing system (MICOS) and as a secreted apolipoprotein. Within mitochondria, APOO is an integral subunit of the MICOS complex, directly interacting with MIC60 and MIC19 to stabilize cristae junctions; this interaction is essential for maintaining cristae architecture, ATP production, and the regulation of cytochrome c release. Its expression is transcriptionally regulated by liver X receptor (LXR), peroxisome proliferator-activated receptor alpha (PPAR??), and retinoid X receptor (RXR). In the extracellular milieu, APOO associates with high-density lipoproteins and interacts with APOA1 and APOE, suggesting involvement in lipid transport and inflammatory modulation. Disruption of APOO thus impinges on both mitochondrial respiration and lipoprotein metabolism pathways.
In the context of HT29 colorectal adenocarcinoma cells, loss of APOO function enables dissection of mitochondrial dynamics and metabolic reprogramming central to cancer progression. APOO deficiency in this line is expected to compromise cristae organization, leading to reduced oxidative phosphorylation capacity and altered apoptotic sensitivity, phenotypes that can be probed using MitoTracker staining and Seahorse metabolic flux analysis. Moreover, the interplay between APOO-mediated mitochondrial integrity and lipid trafficking may influence colon cancer cell behavior, offering a platform to explore how mitochondrial stress and lipid signals converge to affect drug sensitivity and tumorigenicity.
This polyclonal knockout cell population is suited for a range of advanced applications, including mechanistic studies of mitochondrial dysfunction using Western blotting for MICOS complex components, quantitative RT-qPCR for pathway gene expression, apoptosis assays, and migration assays to assess metastatic potential. Researchers can employ these cells to investigate APOO??s role in colorectal cancer metabolism, mitochondrial cristae organization, and lipid-related signaling, or to screen for modulators of drug sensitivity. For further details or to discuss tailor-made configurations, please contact Ascent Research.
